In the db/db mouse model of type 2 diabetes, chronic treatment with liraglutide markedly reduced AF susceptibility, an effect that was attributed to improvements in atrial conduction and electrical remodelling and a notable decrease in atrial fibrosis 243
In the lungs, DiR-Oral HS lipo showed slightly higher intensity than DiR-HS lipo, though not statistically significant ( Fig
GIP-1 has an anti-inflammatory effect, though GIP-1 level was reduced in obese and T2DM patients
Some, like Ivim, have stopped taking new patients
A trial published in the New England Journal of Medicine found that participants using tirzepatide lost up to 20.9% of their body weight over 72 weeks, with results improving progressively at higher doses across all treatment groups (Jastreboff et al., NEJM, 2022, Michigan residents across the state, from Detroit to the Upper Peninsula, have real and practical access to tirzepatide today